GSK plc 6-K, filed Feb 2, 2023
GSK plc (GSK)
6-K
2023-02-02
For: 2023-02-02
View Original
Added on
April 10, 2026
About this 6-K
GSK plc filed this 6-K on February 2, 2023.
|
|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of February 2023
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 2 February 2023, London UK
Jesduvroq (daprodustat) approved
by US FDA for
anaemia of chronic kidney disease in adults on dialysis
●
Jesduvroq is
the only oral HIF-PHI approved in the US, offering adults on
dialysis with anaemia of chronic kidney disease a new oral
treatment option
Tony Wood, President and Chief Scientific Officer, GSK,
said: "Over
the last several decades, there has been little innovation in
anaemia of CKD. We are proud to have
developed Jesduvroq as
a new oral treatment where there is a patient desire for more
options."
The FDA approval is based on results from
the ASCEND-D trial, assessing the efficacy and safety
of Jesduvroq for
the treatment of anaemia of CKD in patients on
dialysis. Results were
published in the New England
Journal of Medicine with additional
results published
in the New England
Journal of Medicine supplementary appendix.
CKD is an increasing global health burden affecting 700 million
patients worldwide, with an estimated one in seven patients also
developing anaemia.[1],[2] When
left untreated or undertreated, anaemia of CKD is associated with
poor clinical outcomes and leads to a substantial burden on
patients and healthcare systems.[3] There
is an unmet need for oral treatment options with efficacy and
safety comparable to current treatments.
LaVarne Burton, President and Chief Executive Officer, American
Kidney Fund, said: "Anaemia
of CKD can be a debilitating condition that is challenging to
manage. This news means that patients on dialysis who are living
with anaemia of CKD now have another treatment option to help
manage their anaemia."
A marketing authorisation application for daprodustat is currently
under review with the European Medicines Agency, with a regulatory
decision anticipated in the first half of 2023.
In June
2020, daprodustat
tablets were approved by Japan's Ministry of Health, Labour and
Welfare for the treatment of patients with anaemia of CKD. In
Japan, the brand name for daprodustat is Duvroq,
where it is the market leader and preferred
HIF-PHI.
About Jesduvroq (daprodustat)
Jesduvroq, a HIF-PHI, belongs
to a novel class of oral medicines for the treatment of anaemia of
CKD in adult patients on dialysis. Inhibition of oxygen-sensing
prolyl hydroxylase enzymes stabilises hypoxia-inducible factors,
which can lead to transcription of erythropoietin and other genes
involved in the correction of anaemia, similar to the physiological
effects that occur in the human body at high
altitude.[4],[5] Jesduvroq provides
an oral treatment option for adult patients with anaemia of CKD on
dialysis.[6] Jesduvroq is
a tablet available in 5 dosage strengths: 1mg, 2mg, 4mg, 6mg,
8mg.
About the ASCEND Phase III clinical trial programme
The ASCEND programme included five Phase III trials to assess the
efficacy and safety profile of daprodustat for the treatment of
anaemia of CKD across the disease spectrum. The programme enrolled
over 8,000 patients who were treated for up to 4.26 years. Results
from all five trials were presented at the American Society of
Nephrology's Kidney Week 2021.
Results from the pivotal cardiovascular outcomes trial, ASCEND-D,
which investigated patients on dialysis, were published in
the New England Journal of
Medicine:6
●
ASCEND-D (Anaemia
Studies in CKD: Erythropoiesis via a Novel PHI
Daprodustat-Dialysis) enrolled 2,964 dialysis patients with anaemia
of CKD who were switched to receive daprodustat ESA
control from a standard of care ESA therapy. A uniform iron
management protocol was instituted across both arms of the study.
The study met its primary efficacy and safety endpoints. Results
showed daprodustatimproved or maintained Hb within target
levels (10-11.5 g/dL) for these patients, and the primary safety
analysis of the ITT population showed that daprodustatachieved
non-inferiority of MACE compared to ESA
control.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at gsk.com/company
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim
Foley
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Dan
Smith
|
+44 (0)
20 8047 5502
|
(London)
|
|
|
Kathleen
Quinn
|
+1 202
603 5003
|
(Washington
DC)
|
|
|
Lyndsay
Meyer
|
+1 202
302 4595
|
(Washington
DC)
|
|
|
|
|
|
|
Investor
Relations:
|
Nick
Stone
|
+44 (0)
7717 618834
|
(London)
|
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
|
Mick
Readey
|
+44 (0)
7990 339653
|
(London)
|
|
|
Josh
Williams
|
+44 (0)
7385 415719
|
(London)
|
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
|
|
Frannie
DeFranco
|
+1 215
751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q4 Results for 2022 and
any impacts of the COVID-19 pandemic.
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
[1] Bikbov
B, Purcell CA, Levey AS, et al. Global, regional, and national
burden of chronic kidney disease, 1990-2017: a systematic analysis
for the Global Burden of Disease Study
2017. Lancet.
2020;395(10225):709-733.
[2] Stauffer
et al. Prevalence of anemia in chronic kidney disease in the United
States. PLoS
One. 2014;9(1):e84943.
[3] Hanna
RM et al. Burden of anemia in chronic kidney disease: beyond
erythropoietin. Adv
Ther. 2021;38(1):52-75.
[4] Ariazi
JL, Duffy KJ, Adams DF, et al. Discovery and preclinical
characterization of GSK1278863 (daprodustat), a small molecule
hypoxia inducible factor-prolyl hydroxylase inhibitor for
anemia. J Pharmacol
Exp Ther. 2017;363(3):336-347.
[5] Maxwell
PH, Eckardt KU. HIF prolyl hydroxylase inhibitors for the treatment
of renal anaemia and beyond. Nat Rev
Nephrol. 2016;12(3):157-168.
[6] Singh
A, et al. Daprodustat for the Treatment of Anemia in Patients
Undergoing Dialysis. N Engl J
Med. 2021;385:2325-2335.
[7] Hill
NR, Fatoba ST, Oke JL, et al. Global prevalence of chronic kidney
disease - A systematic review and
meta-analysis. PLoS
One.
2016;11(7):e0158765.
[8] Palaka
E, et al. The Impact of CKD Anaemia on Patients: Incidence, Risk
Factors, and Clinical Outcomes-A Systematic Literature
Review. Int J
Nephrol. 2020 Jul
1;2020:769;2376
[9]St Peter
WL, Guo H, Kabadi S, et al. Prevalence, treatment patterns, and
healthcare resource utilization in Medicare and commercially
insured non-dialysis-dependent chronic kidney disease patients with
and without anemia in the United States. BMC
Nephrol.
2018;19(1):67.
[10] United
States Renal Data System. 2022 USRDS Annual Data Report:
Epidemiology of kidney disease in the United States. National
Institutes of Health, National Institute of Diabetes and Digestive
and Kidney Diseases, Bethesda, MD, 2022. Available at:
https://usrds-adr.niddk.nih.gov/2022/end-stage-renal-disease/1-incidence-prevalence-patient-characteristics-and-treatment-modalities
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: February
02, 2023
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|